secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0000950170-24-062739
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium
-----------------------------------------------------------------------

- CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.
- Voruciclib is an oral CDK inhibitor; ongoing Phase 1b in relapsed/refractory AML targeting resistance mechanisms.
- Specific efficacy/safety results are detailed in the attached corporate presentation (Exhibit 99.1) but not excerpted in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/0000950170-24-062739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/meip-20240521.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-062739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer